

# Gayatri Mukherjee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8712570/publications.pdf>

Version: 2024-02-01

13  
papers

201  
citations

1306789

7  
h-index

1125271

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic potential of curcumin in endometrial disorders: Current status and future perspectives. <i>Drug Discovery Today</i> , 2022, 27, 900-911.	3.2	4
2	Plasma therapy: a passive resistance against the deadliest. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	5
3	Peptide-MHC complexes: dressing up to manipulate T cells against autoimmunity and cancer. <i>Immunotherapy</i> , 2022, 14, 337-350.	1.0	1
4	High-resolution crystal structure of LpqH, an immunomodulatory surface lipoprotein of <i>Mycobacterium tuberculosis</i> reveals a distinct fold and a conserved cleft on its surface. <i>International Journal of Biological Macromolecules</i> , 2022, 210, 494-503.	3.6	3
5	Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring. <i>Frontiers in Sensors</i> , 2022, 3, .	1.7	6
6	Heterophilic recognition between E-cadherin and N-cadherin relies on same canonical binding interface as required for E-cadherin homodimerization. <i>Archives of Biochemistry and Biophysics</i> , 2022, 727, 109329.	1.4	4
7	Structural Insights into N-terminal IgV Domain of BTNL2, a T Cell Inhibitory Molecule, Suggests a Non-canonical Binding Interface for Its Putative Receptors. <i>Journal of Molecular Biology</i> , 2020, 432, 5938-5950.	2.0	13
8	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. <i>Cancer Reports</i> , 2019, 2, e1160.	0.6	26
9	Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses. <i>Molecular Therapy</i> , 2016, 24, 146-155.	3.7	65
10	Glucagon-reactive islet-infiltrating CD <sup>8</sup> T cells in NOD mice. <i>Immunology</i> , 2015, 144, 631-640.	2.0	9
11	Compensatory Mechanisms Allow Undersized Anchor-Deficient Class I MHC Ligands To Mediate Pathogenic Autoreactive T Cell Responses. <i>Journal of Immunology</i> , 2014, 193, 2135-2146.	0.4	25
12	DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8 <sup>+</sup> T cells independently of PD-1 and PD-L1. <i>International Immunology</i> , 2013, 25, 651-660.	1.8	21
13	Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8 <sup>+</sup> T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13682-13687.	3.3	18